The effects of atamestane and toremifene alone and in combination compared with letrozole on bone, serum lipids and the uterus in an ovariectomized rat model
- 25 October 2006
- journal article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 103 (3) , 293-302
Abstract
We compared the effects of atamestane (ATA) and toremifene (TOR) alone and in combination, with letrozole (LET) on bone, serum lipids and the uterus in ovariectomized (OVX) rats after 16 weeks of treatment. Compared to OVX controls lumbar vertebral and femoral BMD as well as mechanical strength and trabecular bone volume were significantly greater in animals given ATA, TOR or ATA + TOR. The effects of ATA were not reversed by the androgen receptor blocker, flutamide (FLT). Serum cholesterol, low-density lipoprotein cholesterol and triglycerides were reduced by TOR and ATA + TOR whereas they remained unchanged in animals receiving ATA, ATA + FLT, and LET. The uterine epithelium in OVX animals was equally stimulated by TOR and ATA + TOR and unaffected by ATA or LET. Intact animals had significant atrophy of the uterine epithelium when receiving ATA. In summary, TOR alone or in combination with ATA had a predictable stimulatory effect on bone and the uterine epithelium while reducing key parameters of lipid metabolism. In contrast, ATA but not LET had an unexpected stimulatory effect on the OVX rat’s bone and this was not reversed by the anti-androgen FLT leaving this finding unexplained for now. ATA is distinct from LET on end-organ function and this favorable profile makes clinical testing of this steroidal aromatase inhibitor of interest in the clinical setting.Keywords
This publication has 40 references indexed in Scilit:
- Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal WomenBreast Cancer Research and Treatment, 2005
- Crossover trial for lipid abnormality in postmenopausal breast cancer patients during selective estrogen receptor modulators (SERMs) administrationsBreast Cancer Research and Treatment, 2004
- Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipidsBreast Cancer Research and Treatment, 2004
- A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast CancerNew England Journal of Medicine, 2003
- Comparison of the effects of EM-652 (SCH57068), tamoxifen, toremifene, droloxifene, idoxifene, GW-5638 and raloxifene on the growth of human ZR-75-1 breast tumors in nude miceInternational Journal of Cancer, 2002
- Effects of Oral Administration of Tamoxifen, Toremifene, Dehydroepiandrosterone, and Vorozole on Uterine Histomorphology in the RatProceedings of the Society for Experimental Biology and Medicine, 2000
- Metabolism of the steroidal aromatase inhibitor atamestane in rats, cynomolgus monkeys and humansEuropean Journal of Drug Metabolism and Pharmacokinetics, 1994
- Comparison of the effects of the irreversible aromatase inhibitor exemestane with atamestane and MDL 18962 in rats with DMBA-induced mammary tumoursEuropean Journal of Cancer and Clinical Oncology, 1991
- Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the ratJournal of Steroid Biochemistry, 1990
- Effects of anti-estrogens on bone in castrated and intact female ratsBreast Cancer Research and Treatment, 1987